Osteotech’s Biocomposite Receives FDA Clearance

July 30, 2008

The FDA has granted 510(k) clearance to Osteteotech for its Plexur M biocomposite for use in spinal applications.

The product may be used with autograft as a bone void filler in the spine. It is the second bone-polymer biocomposite developed under the company’s Plexur technology, Osteotech said.

In March, the company received FDA clearance to use the product in filling bony gaps in the pelvis and extremities.